|
Basic Characteristics of Mutations
|
|
Mutation Site
|
H274Y |
|
Mutation Site Sentence
|
Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
NA |
|
Standardized Encoding Gene
|
NA
|
|
Genotype/Subtype
|
H1N1 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Influenza A
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
oseltamivir |
|
Location
|
Japan |
|
Literature Information
|
|
PMID
|
19015327
|
|
Title
|
Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice
|
|
Author
|
Baz M,Abed Y,Nehme B,Boivin G
|
|
Journal
|
Antimicrobial agents and chemotherapy
|
|
Journal Info
|
2009 Feb;53(2):791-3
|
|
Abstract
|
The new oral neuraminidase (NA) inhibitor A-322278 was evaluated in mice infected with influenza A/H1N1 wild-type virus or the oseltamivir-resistant (H274Y mutant) virus. A-322278 decreased mortality rates and lung virus titers significantly more than oseltamivir in mice infected with the NA H274Y mutant when therapy was started 4 h before or even 48 h after infection.
|
|
Sequence Data
|
-
|